Genzyme puts weight behind Myozyme, Lumizyme with Belgian plant
This article was originally published in Scrip
Executive Summary
Genzyme has started building an additional €250 million manufacturing plant in Geel, Belgium to support long-term growth of its Pompe disease treatments Myozyme and Lumizyme (both alglucosidase alfa). Commercial approvals for the new site, which will add 8,000 litres of production capacity at Geel, are expected from late 2014. Genzyme is already boosting capacity for Myozyme and Lumizyme at its adjacent plant in Geel, with the addition of a third bioreactor scheduled for approval by the end of this year.
You may also be interested in...
All The Way To The Top: Diversity And Inclusion In Pharma Leadership
Policies, programs and strategies promoting diversity and inclusion are almost as ubiquitous in the pharmaceutical industry these days as environmental commitments. That reflects enormous cultural change over the last few generations, hastened in recent history by initiatives such as MeToo or Black Lives Matter.
HemaQuest expands Phase II remit for HQK-1001 in sickle cell disease
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis withdraws European application for 'personalised' lumiracoxib
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.